NMRA-CK1δ

About Neumora Therapeutics

Neumora Therapeutics is a clinical-stage biotech company founded in 2019 with a mission to revolutionize neuroscience drug development through data-driven precision medicine. Its core strategy involves using a proprietary platform to identify biologically defined patient populations and advance a pipeline of novel, best-in-class therapeutics for major depressive disorder, schizophrenia, Alzheimer's agitation, and Parkinson's disease. The company's lead asset, navacaprant, is a novel kappa opioid receptor antagonist in Phase 3 development for MDD, representing a significant near-term catalyst.

Therapeutic Areas